Stability of seasonal influenza vaccines investigated by spectroscopy and microscopy methods

Vaccine

Volumn 29, Issue 43, 2011, Pages 7404-7413

  Patois, E ^a,b   Capelle, M A H ^c   Gurny, R ^a,b   Arvinte, T ^a,b,c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Therapeomic Inc   (Switzerland)

Author keywords

Fluorescence spectroscopy; Influenza vaccines; Light scattering; Nile Red fluorescence microscopy; Physical stability

Indexed keywords

EXCIPIENT; INFLUENZA VACCINE;

ARTICLE; DRUG SCREENING; DRUG STABILITY; DRUG STORAGE; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPY; FLUORESCENCE SPECTROSCOPY; FREEZE THAWING; INFLUENZA VACCINATION; LIGHT SCATTERING; PRIORITY JOURNAL; SEASONAL INFLUENZA; STORAGE TEMPERATURE; TEMPERATURE STRESS;

DRUG STABILITY; DRUG STORAGE; INFLUENZA VACCINES; MICROSCOPY, FLUORESCENCE; SPECTROMETRY, FLUORESCENCE; SPECTRUM ANALYSIS; TEMPERATURE; VACCINES, SUBUNIT;

EID: 80053444734     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.067     Document Type: Article

References (63)

1. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25(39-40):6852-6862.
2. Webby R.J., Sandbulte M.R. Influenza vaccines. Front Biosci 2008, 13:4912-4924.
3. Brandau D.T., Jones L.S., Wiethoff C.M., Rexroad J., Middaugh C.R. Thermal stability of vaccines. J Pharm Sci 2003, 92(2):218-231.
4. Coenen F., Tolboom J.T.B.M., Frijlink H.W. Stability of influenza sub-unit vaccine. Does a couple of days outside the refrigerator matter?. Vaccine 2006, 24(4):525-531.
5. Luykx D.M.A.M., Casteleijn M.G., Jiskoot W., Westdijk J., Jongen P.M. Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. Eur J Pharm Sci 2004, 23(1):65-75.
6. Buckland B.C. The process development challenge for a new vaccine. Nat Med 2005, 11(4):S16-S19.
7. Manning M.C., Chou D.K., Murphy B.M., Payne R.W., Katayama D.S. Stability of protein pharmaceuticals: an update. Pharm Res 2010, 27(4):544-575.
8. Manning M.C., Patel K., Borchardt R.T. Stability of protein pharmaceuticals. Pharm Res 1989, 6(11):903-918.
9. Fagain C. Understanding and increasing protein stability. BBA-Protein Struct M 1995, 1252(1):1-14.
10. Arakawa T., Prestrelski S.J., Kenney W.C., Carpenter J.F. Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev 2001, 46(1-3):307-326.
11. Arvinte T. Concluding remarks: analytical methods for protein formulations. Methods for structural analysis of protein pharmaceuticals 2005, 661-666. AAPS Press. W. Jiskoot, D.J. Crommelin (Eds.).
12. Renfrey S., Watts A. Morphological and biochemical-characterization of influenza vaccines commercially available in the United-Kingdom. Vaccine 1994, 12(13):747-752.
13. Le Tallec D., Doucet D., Elouahabi A., Harvengt P., Deschuyteneer M., Deschamps M. Cervarix™, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions. Hum Vaccines 2009, 5(7):467-474.
14. Gentile M.A., Melchiorre S., Emolo C., Moschioni M., Gianfaldoni C., Pancotto L., et al. Structural and functional characterization of the streptococcus pneumoniae RrgB pilus backbone D1 Domain. J Biol Chem 2011, 286(16):14588-14597.
15. Apicella M.A., Post D.M.B., Fowler A.C., Jones B.D., Rasmussen J.A., Hunt J.R., et al. Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis. PLoS One 2010, 5(7):e11060.
16. Cuello M., Cabrera O., Martinez I., del Campo J.M., Camaraza M.A., Sotolongo F., et al. New meningococcal C polysaccharide-tetanus toxoid conjugate: physico-chemical and immunological characterization. Vaccine 2007, 25(10):1798-1805.
17. Wei Z., McEvoy M., Razinkov V., Polozova A., Li E., Casas-Finet J., et al. Biophysical characterization of influenza virus subpopulations using field flow fractionation and multiangle light scattering: correlation of particle counts, size distribution and infectivity. J Virol Methods 2007, 144(1-2):122-132.
18. Garcia-Canas V., Lorbetskie B., Bertrand D., Cyr T.D., Girard M. Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection. Anal Chem 2007, 79(8):3164-3172.
19. Garcia-Canas V., Lorbetskie B., Cyr T.D., Hefford M.A., Smith S., Girard M. Approach to the profiling and characterization of influenza vaccine constituents by the combined use of size-exclusion chromatography, gel electrophoresis and mass spectrometry. Biologicals 2010, 38(2):294-302.
20. ® V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002, 20:B17-B23.
21. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 2005, 23:S26-S38.
22. Demeester J., De Smedt S.S., Sanders N.N., Haustraede J. Light scattering. Methods for structural analysis of protein pharmaceuticals 2005, 245-275. AAPS Press. W. Jiskoot, D.J. Crommelin (Eds.).
23. Fernandez C., Minton A.P. Static light scattering from concentrated protein solutions. II. Experimental test of theory for protein mixtures and weakly self-associating proteins. Biophys J 2009, 96(5):1992-1998.
24. Demeule B., Lawrence M.J., Drake A.F., Gurny R., Arvinte T. Characterization of protein aggregation: the case of a therapeutic immunoglobulin. BBA-Proteins Proteom 2007, 1774(1):146-153.
25. Capelle M., Arvinte T., Brügger P. Spectroscopic characterization of antibodies adsorbed to aluminium adjuvants: correlation with antibody vaccine immunogenicity. Vaccine 2005, 23:1686-1694.
26. Jiskoot W., Visser A.J.W.G., Herron J.N., Sutter M. Fluorescence spectroscopy. Methods for structural analysis of protein pharmaceuticals 2005, 27-82. AAPS Press. W. Jiskoot, D.J. Crommelin (Eds.).
27. Jorgensen L., Moeller E.H., van de Weert M., Nielsen H.M., Frokjaer S. Preparing and evaluating delivery systems for proteins. Eur J Pharm Sci 2006, 29(3-4):174-182.
28. Taschner N., Muller S.A., Alumella V.R., Goldie K.N., Drake A.F., Aebi U., et al. Modulation of antigenicity related to changes in antibody flexibility upon lyophilization. J Mol Biol 2001, 310(1):169-179.
29. Dusa A., Kaylor J., Edridge S., Bodner N., Hong D.P., Fink A.L. Characterization of oligomers during alfa-synuclein aggregation using intrinsic tryptophan fluorescence. Biochemistry-US 2006, 45(8):2752-2760.
30. Souillac P.O. Biophysical characterization of insoluble aggregates of a multi-domain protein: an insight into the role of the various domains. J Pharm Sci 2005, 94(9):2069-2083.
31. Rexroad J., Wiethoff C.M., Green A.P., Kierstead T.D., Scott M.O., Middaugh C.R. Structural stability of adenovirus type 5. J Pharm Sci 2003, 92(3):665-678.
32. Kissmann J., Joshi S.B., Haynes J.R., Dokken L., Richardson C., Middaugh C.R. H1N1 influenza virus-like particles: physical degradation pathways and identification of stabilizers. J Pharm Sci 2011, 100(2):634-645.
33. Demeule B., Gurny R., Arvinte T. Detection and characterization of protein aggregates by fluorescence microscopy. Int J Pharm 2007, 329(1-2):37-45.
34. Barr I.G., McCauley J., Cox N., Daniels R., Engelhardt O.G., Fukuda K., et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine 2010, 28(5):1156-1167.
35. WHO Recommended composition of influenza virus vaccines for use in the 2009-2010 influenza season (northern hemisphere winter). Weekly Epidemiol Rec 2009, 84(9):65-76. http://www.who.int/wer/2009/wer8409.pdf.
36. Lakowicz J.R. Time-domain lifetime measurements. Principles of fluorescence spectroscopy 1999, 95-140. Kluwer Academic/Plenum Publishers, NewYork. J.R. Lakowicz (Ed.).
37. Chen Y., Barkley M.D. Toward understanding tryptophan fluorescence in proteins. Biochemistry-US 1998, 37(28):9976-9982.
38. 2.19.19 particulate contamination: sub-visible particles. The European pharmacopoeia 2008, The European Directorate for the Quality of Medicines & Healthcare. 6.1 ed.
39. Nayar R., Hope M.J., Cullis P.R. Generation of large unilamellar vesicles from long-chain saturated phosphatidylcholines by extrusion technique. Biochim Biophys Acta 1989, 986(2):200-206.
40. Higgins J., Hodges N.A., Olliff C.J., Phillips A.J. Factors influencing cryoprotective activity and drug leakage from liposomes after freezing. J Pharm Pharmacol 1986, 38(4):259-263.
41. Greenspan P., Fowler S.D. Spectrofluorometric studies of the lipid probe, Nile Red. J Lipid Res 1985, 26(7):781-789.
42. European Pharmacopoeia 01/2005:0158. Influenza vaccine (split virion, inactivated); 2005.
43. European Pharmacopoeia 01/2005:0869. Influenza vaccine (surface antigen, inactivated); 2005.
44. European Pharmacopoeia 01/2005:2053: Influenza vaccine (surface antigen, inactivated, virosome); 2005.
45. Shaw M.L., Stone K.L., Colangelo C.M., Gulcicek E.E., Palese P. Cellular proteins in influenza virus particles. PLoS Pathog 2008, 4(6):e1000085.
46. Morozova-Roche L. A false paradise - mixed blessings in the protein universe: the amyloid as a new challenge in drug development. Curr Med Chem 2007, 14:1221-1230.
47. Weiss W.F., Young T.M., Roberts C.J. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci 2009, 98(4):1246-1277.
48. Murphy R.M., Kendrick B.S. Protein misfolding and aggregation. Biotechnol Progr 2007, 23(3):548-552.
49. Mahler H.C., Friess W., Grauschopf U., Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci 2009, 98(9):2909-2934.
50. Morris A.M., Watzky M.A., Finke R.G. Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. BBA-Proteins Proteom 2009, 1794(3):375-397.
51. Wang W., Nema S., Teagarden D. Protein aggregation - pathways and influencing factors. Int J Pharm 2010, 390(2):89-99.
52. Cromwell M.E., Hilario E., Jacobson F. Protein aggregation and bioprocessing. AAPS J 2006, 8(3):E572-E579.
53. McGraw-Hill dictionary of scientific and technical terms 2003, McGraw-Hill, New York. 6th ed.
54. Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., Ignatenko S., et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371(9615):821-827.
55. ® cells: a novel RP-HPLC method. Vaccine 2006, 24(16):3137-3144.
56. Palache B. New vaccine approaches for seasonal and pandemic influenza. Vaccine 2008, 26(49):6232-6236.
57. Babiuk S., Skowronski D.M., De Serres G., HayGlass K., Brunham R.C., Babiuk L. Aggregate content influences the Thl/Th2 immune response to influenza vaccine: evidence from a mouse model. J Med Virol 2004, 72(1):138-142.
58. CPMP Note for guidance on harmonisation of requirements for influenza vaccines 1997, EMEA. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
59. Thomas P.G., Keating R., Hulse-Post D.J., Doherty P.C. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006, 12(1):48-54.
60. Moss P. Cellular immune responses to influenza. Dev Biol (Basel) 2003, 115:31-37.
61. Moldoveanu Z., Clements M.L., Prince S.J., Murphy B.R., Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995, 13(11):1006-1012.
62. Johansson B.E., Brett I.C. Changing perspective on immunization against influenza. Vaccine 2007, 25(16):3062-3065.
63. Girard M.P., Cherian T., Pervikov Y., Kieny M.P. A review of vaccine research and development: human acute respiratory infections. Vaccine 2005, 23(50):5708-5724.